Define Scope and Strategic Fit for Horizon Participation
Establish why the venture is seeking Horizon Europe or international consortium grant funding at this specific growth phase. Map how non-dilutive collaborative R&D funding aligns with the technology roadmap without distracting from commercial go-to-market priorities.
Clarifying the purpose ensures the venture engages with European consortiums for strategic advantage rather than desperate grant chasing. It aligns non-dilutive funding targets with core IP development, preventing costly strategic drift across complex multi-partner programmes.
The founder must document a clear strategic rationale linking Horizon funding to specific technological or validation milestones. This must include explicit boundaries on acceptable IP leakage, time commitments, and required match-funding capacity.
Five questions an expert would ask when reviewing your output
Use these to challenge assumptions, pressure-test your logic, and check the quality of this action's output in the context of the parent task and wider venture development.
- 1
What specific technological milestone are you targeting through Horizon that cannot be funded faster by private capital or domestic grants?
- 2
How will participating in a multi-partner European consortium impact your core product roadmap and go-to-market timeline?
- 3
What operational evidence demonstrates that your team has the capacity to manage EU administrative overhead without compromising core execution?
- 4
Why is a collaborative consortium structure superior to an internal R&D effort for this specific innovation?
- 5
How does this funding call align with your long-term venture valuation and subsequent private investment rounds?